EvaluatePharma World Preview 2016, Outlook to 2022
Worldwide Rx Sales Forecast to Grow 6.3% p.a. to 2022
The ninth edition of the EvaluatePharma World Preview 2016, Outlook to 2022 report brings together many of our analyses to provide a top level insight, from the world's financial markets, into the expected performance of the industry between now and 2022.
New this year - Worldwide Pharma Innovation 2008-2022 including insights into the companies with most valuable pipelines based on NPV analysis.
Worldwide prescription drug sales predicted to grow 6.3% (CAGR) between 2016 and 2022.
$169 billion in additional prescription drug sales in 2022 to come from R&D projects.
Novartis and Roche to compete head-to-head for the title of worldwide prescription drug sales in 2022; Pfizer to challenge them following the Medivation acquisition.
Worldwide pharmaceutical R&D spend expected to grow by 2.8% (CAGR) to $182 billion in 2022.
Celgene and Shire forecast to record the fastest sales growth (CAGR) by 2022 with increases of 16% and 19%, respectively.
New drug approvals in 2015 reach a record 56 NMEs, topping 2014’s record of 50
Oncology remains the largest therapy area in sales with a 12.5% (CAGR) growth rate from 2016 to 2022.
View EvaluatePharma World Preview 2016, Outlook to 2022 Executive Summary